Cognitive function in post-treatment Lyme disease Do additional antibiotics help?

University of Connecticut School of Medicine, Farmington, USA.
Neurology (Impact Factor: 8.3). 07/2003; 60(12):1916-22. DOI: 10.1212/01.WNL.0000068030.26992.25
Source: PubMed

ABSTRACT It is controversial whether additional antibiotic treatment will improve cognitive function in patients with post-treatment chronic Lyme disease (PTCLD).
To determine whether antibiotic therapy improves cognitive function in two randomized double-blind placebo-controlled studies of patients with PTCLD.
A total of 129 patients with a physician-documented history of Lyme disease from three study sites in the northeast United States were studied. Seventy-eight were seropositive for IgG antibodies against Borrelia burgdorferi, and 51 were seronegative. Patients in each group were randomly assigned to receive IV ceftriaxone 2 g daily for 30 days followed by oral doxycycline 200 mg daily for 60 days or matching IV and oral placebos. Assessments were made at 90 and 180 days after treatment. Symptom severity was measured from the cognitive functioning, pain, and role functioning scales of the Medical Outcomes Study (MOS). Memory, attention, and executive functioning were assessed using objective tests. Mood was assessed using the Beck Depression Inventory and Minnesota Multiphasic Personality Inventory.
There were no significant baseline differences between seropositive and seronegative groups. Both groups reported a high frequency of MOS symptoms, depression, and somatic complaints but had normal baseline neuropsychological test scores. The combined groups showed significant decreases in MOS symptoms, higher objective test scores, and improved mood between baseline and 90 days. However, there were no significant differences between those receiving antibiotics and placebo.
Patients with post-treatment chronic Lyme disease who have symptoms but show no evidence of persisting Borrelia infection do not show objective evidence of cognitive impairment. Additional antibiotic therapy was not more beneficial than administering placebo.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Most physicians prescribe Lyme disease antibiotic therapy regimens that are recommended by the Centers for Disease Control and Prevention, the Infectious Disease Society of America, and the National Institutes of Health. An alternative approach by some physicians consists of prolonged antibiotic treatment for >2 months because they believe that Lyme disease often results in persistent Borrelia burgdorferi infection. Understanding how patients perceive the disease is important for effective doctor-patient communication. We conducted interviews and surveys on Block Island, Rhode Island, and Storrs, Connecticut, to explore the public perception of persistent symptoms following Lyme disease and the need for long-term treatment. Most of our participants believed that symptoms and the Lyme disease bacteria can persist after antimicrobial therapy for Lyme disease. When asked about the value of continuing antibiotic treatment for >2 months, about half thought that it was sometimes useful and about a quarter thought it was always useful. Almost all of the respondents stated that they knew people who had experienced Lyme disease, and these personal observations were more frequently cited as an important source of Lyme disease information than official sources such as medical professionals. We conclude that healthcare workers should review the scientific literature regarding appropriate therapy for Lyme disease, discuss such information with their patients, and identify sources of information that their patients can review. Medical societies, private foundations, and State and Federal Health agencies should increase efforts to educate physicians and the general public about the standard diagnosis and treatment of Lyme disease and provide additional funding to determine why some people experience persistent symptoms following this infection.
    Vector borne and zoonotic diseases (Larchmont, N.Y.) 03/2011; 11(7):857-62. DOI:10.1089/vbz.2010.0116 · 2.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Within both the biomedical and lay community, Lyme disease continues to evoke considerable disagreements, especially regarding its diagnosis, patient management and treatment. A recent article of mine, published in this journal, dealing primarily with therapy for Lyme disease, subsequently led to a highly critical commentary on some of its content. Too often, however, the authors of these criticisms came to premature conclusions based mostly on little or no published data. Instead, they relied almost exclusively on highly speculative theories and on citing the uncorroborated published or unpublished findings and anecdotal reports of others in an attempt to substantiate their weak claims. In this reply account of mine, I respond by providing compelling evidence, derived primarily from the extensive peer-reviewed published literature, that runs counter to most of their key critical concerns. Another goal here is to further clarify certain inconsistencies, related to the epidemiology and microbiology of Lyme disease and its causative agent, including the dubious 'cyst forms', that have an important bearing on therapy.
    Expert Opinion on Investigational Drugs 11/2003; 12(10):1615-20. DOI:10.1517/13543784.12.10.1615 · 5.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Eleven patients with neuro-borreliosis had been treated with 200 mg fluconazole daily for 25 days after an unsuccessful therapy with antibiotics. At the end of treatment eight patients had no borreliosis symptoms and remained free of relapse in a follow-up examination one year later. In the remaining four patients, symptoms were considerably improved. At the end of therapy immune reactivity (IgM+) disappeared in three patients. Since borrelia spp. are almost exclusively localised intracellular, they may depend on certain metabolites of their eucaryotic host cell. Inhibition of P450 and other cytochromes by fluconazole may incapacitate Borrelia upon longterm exposure.
    European journal of medical research 08/2004; 9(7):334-6. · 1.40 Impact Factor

Preview (2 Sources)

Available from